- Home
- CNC vs UTHR Comparison
CNC vs UTHR Comparison
Compare CNC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNC
- UTHR
- Stock Information
- Founded
- CNC 1984
- UTHR 1996
- Country
- CNC United States
- UTHR United States
- Employees
- CNC N/A
- UTHR N/A
- Industry
- CNC Medical Specialities
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- CNC Health Care
- UTHR Health Care
- Exchange
- CNC Nasdaq
- UTHR Nasdaq
- Market Cap
- CNC 15.6B
- UTHR 13.4B
- IPO Year
- CNC 2001
- UTHR 1999
- Fundamental
- Price
- CNC $25.92
- UTHR $294.28
- Analyst Decision
- CNC Hold
- UTHR Buy
- Analyst Count
- CNC 18
- UTHR 13
- Target Price
- CNC $47.88
- UTHR $379.69
- AVG Volume (30 Days)
- CNC 22.9M
- UTHR 459.9K
- Earning Date
- CNC 07-25-2025
- UTHR 07-30-2025
- Dividend Yield
- CNC N/A
- UTHR N/A
- EPS Growth
- CNC N/A
- UTHR 17.94
- EPS
- CNC 4.07
- UTHR 25.63
- Revenue
- CNC $159,560,000,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- CNC $26.60
- UTHR $14.37
- Revenue Next Year
- CNC $0.33
- UTHR $6.59
- P/E Ratio
- CNC $6.37
- UTHR $11.49
- Revenue Growth
- CNC 10.57
- UTHR 17.62
- 52 Week Low
- CNC $25.12
- UTHR $266.98
- 52 Week High
- CNC $80.59
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- CNC 24.97
- UTHR 49.57
- Support Level
- CNC $25.11
- UTHR $272.12
- Resistance Level
- CNC $26.88
- UTHR $307.71
- Average True Range (ATR)
- CNC 1.34
- UTHR 8.47
- MACD
- CNC 0.57
- UTHR -1.25
- Stochastic Oscillator
- CNC 13.90
- UTHR 62.26
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.